S. Zhai

发表

Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms

E. Sausville, S. Arbuck, G. Melillo, 2003, Anti-cancer drugs.

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.

E. Sausville, S. Arbuck, S. Swain, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma.

E. Sausville, W. Figg, S. Zhai, 2002, Biomedical chromatography : BMC.

COMPARATIVE INHIBITION OF HUMAN CYTOCHROMES P 450 1 A 1 AND 1 A 2 BY FLAVONOIDS

S. Zhai, R. Vestal, R. Dai, 1998 .

Inhibition of human cytochrome P450 1A2 by flavones: A molecular modeling study

M. Pincus, S. Zhai, X. Wei, 1998, Journal of protein chemistry.

Dose‐Dependent Effect of Piragliatin, a Glucokinase Activator, on the QT Interval Following Short‐Term Multiple Doses in Patients With Type 2 Diabetes Mellitus

J. Zhi, S. Zhai, M. Boldrin, 2017, Clinical pharmacology in drug development.

Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus

J. Zhi, S. Zhai, 2016, Journal of clinical pharmacology.

Lack of Potential Pharmacokinetic and Pharmacodynamic Interactions Between Piragliatin, a Glucokinase Activator, and Simvastatin in Patients With Type 2 Diabetes Mellitus

J. Zhi, S. Zhai, M. Boldrin, 2016, Journal of clinical pharmacology.

Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Piragliatin, a Glucokinase Activator, and Glyburide, a Sulfonylurea, in Type 2 Diabetic Patients

J. Zhi, S. Zhai, A. Georgy, 2016, Clinical pharmacology in drug development.

Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients

J. Zhi, S. Zhai, M. Boldrin, 2016, Journal of clinical pharmacology.

A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.

S. Steinberg, S. Cremers, W. Figg, 2005, The Journal of urology.

Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection.

J. Verweij, A. Sparreboom, W. Figg, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques.

B. M. Flynn, P. Duray, D. Schrump, 2002, Journal of Thoracic and Cardiovascular Surgery.

Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia.

S. Zhai, J. Zhang, X. Ke, 2010, International journal of clinical pharmacology and therapeutics.

Brain mitochondrial citrate synthase and glutamate dehydrogenase: Differential inhibition by fatty acyl coenzyme a derivatives

S. Zhai, J. Lai, D. Lu, 1994, Metabolic Brain Disease.

Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women.

L. Nieman, W. Figg, S. Zhai, 2003, Human reproduction.

Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

M. Grever, L. Grochow, R. Donehower, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer

S. Steinberg, S. Swain, A. Tan, 2004, Clinical Cancer Research.

Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.

E. Sausville, A. Sparreboom, W. Figg, 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Simultaneous determination of theophylline, enoxacin and ciprofloxacin in human plasma and saliva by high-performance liquid chromatography.

S. Zhai, R. Vestal, X. Wei, 1995, Journal of chromatography. B, Biomedical applications.

Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.

S. Steinberg, E. Kohn, L. Minasian, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma

S. Steinberg, P. Choyke, T. Fojo, 2004, Clinical Cancer Research.

Pharmacokinetics of Isolated Lung Perfusion with Antitumor Agents

S. Zhai, 2004 .

Laparoscopic continuous hyperthermic peritoneal perfusion.

D L Bartlett, S. Libutti, H. Alexander, 2001, Journal of the American College of Surgeons.

Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.

M. Grever, L. Grochow, R. Donehower, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development

E. Sausville, A. Senderowicz, W. Figg, 2002, The Annals of pharmacotherapy.

Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids.

S. Zhai, R. Vestal, R. Dai, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Inhibition of methoxyresorufin demethylase activity by flavonoids in human liver microsomes.

S. Zhai, X. Wei, R. Vestal, 1998, Life sciences.

Relation between plasma and saliva concentrations of enoxacin, ciprofloxacin, and theophylline.

S. Zhai, R. Vestal, K. Kunze, 1996, Therapeutic drug monitoring.

J. Zhi, S. Zhai, M. Boldrin, 2016, Journal of clinical pharmacology.